Actinium Pharmaceuticals (ATNM) Competitors $1.65 +0.01 (+0.61%) Closing price 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ATNM vs. ACTU, DSGN, ENGN, KOD, TNXP, CRDF, SOPH, VYGR, YMAB, and CRGXShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Actuate Therapeutics (ACTU), Design Therapeutics (DSGN), enGene (ENGN), Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Cardiff Oncology (CRDF), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Actuate Therapeutics Design Therapeutics enGene Kodiak Sciences Tonix Pharmaceuticals Cardiff Oncology SOPHiA GENETICS Voyager Therapeutics Y-mAbs Therapeutics CARGO Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Does the media refer more to ATNM or ACTU? In the previous week, Actinium Pharmaceuticals had 13 more articles in the media than Actuate Therapeutics. MarketBeat recorded 15 mentions for Actinium Pharmaceuticals and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.23 beat Actinium Pharmaceuticals' score of -0.03 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Actuate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ATNM or ACTU? Actinium Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 143.90%. Actuate Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 98.45%. Given Actinium Pharmaceuticals' higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ATNM or ACTU? Actinium Pharmaceuticals received 9 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 47.83% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes1147.83% Underperform Votes1252.17% Actuate TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, ATNM or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K631.62-$48.82M-$1.39-1.18Actuate TherapeuticsN/AN/A-$24.75MN/AN/A Do insiders & institutionals hold more shares of ATNM or ACTU? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ATNM or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Actuate Therapeutics N/A N/A N/A SummaryActuate Therapeutics beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$51.16M$6.47B$5.34B$19.27BDividend YieldN/A2.64%5.28%3.89%P/E Ratio-1.188.4427.0334.33Price / Sales631.62258.46399.4434.89Price / CashN/A65.8538.3217.51Price / Book1.256.416.764.69Net Income-$48.82M$143.95M$3.24B$1.02B7 Day Performance-10.38%-2.06%-1.41%-2.11%1 Month Performance25.19%0.26%6.72%4.25%1 Year PerformanceN/A0.56%18.78%4.87% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.3054 of 5 stars$1.65+0.6%$4.00+142.4%N/A$51.47M$81,000.00-1.1930Trending NewsACTUActuate TherapeuticsN/A$10.26-2.7%$20.50+99.8%N/A$206.06MN/A0.0010Negative NewsGap DownDSGNDesign Therapeutics0.5367 of 5 stars$3.53+0.6%$4.00+13.3%-12.6%$200.40MN/A-4.1540Positive NewsENGNenGene2.6814 of 5 stars$3.91+13.3%$23.29+495.5%-67.0%$199.32MN/A-6.7431News CoverageGap DownKODKodiak Sciences3.6353 of 5 stars$3.71+6.0%$9.00+142.6%+12.1%$195.75MN/A-1.0290TNXPTonix Pharmaceuticals3.4419 of 5 stars$26.60-5.0%$585.00+2,099.2%-94.8%$194.85M$10.04M-0.0150Gap UpHigh Trading VolumeCRDFCardiff Oncology1.6705 of 5 stars$2.91+3.6%$12.00+312.4%-11.9%$193.59M$587,000.00-3.1020Positive NewsSOPHSOPHiA GENETICS1.7476 of 5 stars$2.86-3.4%$6.80+137.8%-39.7%$190.73M$67.17M-2.62520VYGRVoyager Therapeutics4.6099 of 5 stars$3.43+3.9%$13.39+290.4%-64.5%$189.80M$66.96M4.83100Gap UpYMABY-mAbs Therapeutics3.4584 of 5 stars$4.17+1.7%$16.60+298.1%-64.6%$188.83M$87.69M-7.72150CRGXCARGO Therapeutics2.1465 of 5 stars$4.09-0.7%$15.00+266.7%-80.3%$188.59MN/A-0.96116Positive News Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Design Therapeutics Alternatives enGene Alternatives Kodiak Sciences Alternatives Tonix Pharmaceuticals Alternatives Cardiff Oncology Alternatives SOPHiA GENETICS Alternatives Voyager Therapeutics Alternatives Y-mAbs Therapeutics Alternatives CARGO Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
